Intellia Therapeutics Inc (NTLA)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$14.84

Buy

$14.85

arrow-up$1.825 (+14.02%)

Prices updated at 04 Jun 2026, 19:12 EDT

Prices minimum 15 mins delay

Prices in USD

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revo ...

NASDAQ

0.25%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Frank Verwiel, M.B.A.,M.D.

CEO

Dr. John M. Leonard, M.D.

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

377

Head office

40 Erie Street

Cambridge

United States

02139

+1 857 285-6200

lina.li@intelliatx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D. Independent Director	0.06m
Dr. John M. Leonard, M.D. Director, President and Chief Executive Officer	0.71m
Dr. Frank Verwiel, M.B.A.,M.D. Chairman of the Board	0.10m
Mr. Brian Goff Independent Director	0.06m
Mr. William J. Chase Independent Director	0.07m
Dr. Jesse Goodman, M.D.,M.P.H. Independent Director	0.07m
Dr. Georgia Keresty, M.P.H.,PhD Independent Director	0.07m
Mr. James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary	0.49m
Dr. David Lebwohl, M.D. Executive Vice President and Chief Medical Officer	0.54m
Mr. Edward J. Dulac, III Treasurer, Executive Vice President and Chief Financial Officer	0.53m
Ms. Muna Bhanji, Ph. Independent Director	0.07m
Ms. Eliana Clark Executive Vice President and Chief Technology Officer	-
Mr. Michael P. Dube Vice President and Chief Accounting Officer	-
Ms. Birgit Schultes Executive Vice President and Chief Scientific Officer	0.48m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
ARK Investment Management LLC	14,509,247
Vanguard Group Inc	13,010,001
BlackRock Inc	12,155,806
ARK Innovation ETF	11,925,813
ARK Disruptive Innovation Full Composite	9,307,927

Director dealings

Date chevron-l-regular chevron-r-regular	Action
11 Dec 2025	-
11 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
11 Dec 2025	-
11 Dec 2025	-
11 Dec 2025	-
01 Oct 2025	-
01 Oct 2025	-
20 Aug 2025	-
23 Jul 2025	-
02 Jul 2025	-
01 Jul 2025	-
30 Jun 2025	-
01 Jul 2025	-
11 Jun 2025	-
11 Jun 2025	-
11 Jun 2025	-
11 Jun 2025	-
11 Jun 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.